SAMPLE TECH (01708) plans to publicly list for sale part of the land use rights of industrial real estate in Nanjing City.
Sanbao Technology (01708) announced that the company plans to publicly list and sell its assets on the Shenzhen Stock Exchange. Therefore, the board of directors...
SAMPLE TECH (01708) announced that the company plans to sell its assets through a public listing on the stock exchange. Therefore, the board of directors intends to seek shareholders' approval in advance at an extraordinary general meeting to finalize and complete the proposed sale. The reserve price will be determined by the group, but will not be less than approximately RMB 187 million (including value-added tax).
As of the date of this announcement and prior to the proposed sale, the group owns industrial real estate located at No. 10 Maqun Avenue, Qixia District, Nanjing City, Jiangsu Province, China. The real estate registration certificate is Su (2025) Ning Qibudongchanquan No. 0033368, with a land area of 76,760.91 square meters, a building area of 51,932.05 square meters, and a period of use from August 18, 2003 to August 17, 2053, including eight properties. The assets for sale are a portion of the aforementioned real estate and the land use rights within the occupied area of the relevant properties. The group is the sole owner of the real estate rights for the assets for sale. The assets for sale include buildings F1, F3, F4, and F5, with a total building area of 16,955.3 square meters, corresponding to a land area of 13,262.6 square meters, as well as rights to common facilities such as access to public areas, and the use of utilities such as water, electricity, networks, communication, fire protection, and landscaping, as well as non-separable decorations and renovations.
The assets for sale are non-core assets of the group, and the proposed sale will not impact the development of the group's main business. The board of directors believes that the proposed sale (if implemented) will enable the group to optimize its assets, accelerate asset turnover for the company's overall strategic planning; the cash flow generated from the proposed sale will be used to repay loans and borrowing, and reduce the group's interest-bearing liabilities; and supplement the group's general operating funds and the development of its core business.
Related Articles

Health 160 (02656): Hong Kong public offering received 751.77 times oversubcribed, listing on September 17th.

JOIN-SHARE (01543) has entered into a business cooperation agreement with Zhongshan Financial Investment.
Jiangsu Hengrui Pharmaceuticals (01276): Injection SHR-1826, Adelbeli monoclonal antibody injection, Bevacizumab monoclonal antibody injection obtained drug clinical trial approval letter.
Health 160 (02656): Hong Kong public offering received 751.77 times oversubcribed, listing on September 17th.

JOIN-SHARE (01543) has entered into a business cooperation agreement with Zhongshan Financial Investment.

Jiangsu Hengrui Pharmaceuticals (01276): Injection SHR-1826, Adelbeli monoclonal antibody injection, Bevacizumab monoclonal antibody injection obtained drug clinical trial approval letter.